Results 171 to 180 of about 178,774 (332)
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar +5 more
wiley +1 more source
Respirology, EarlyView.ABSTRACT Background and Objectives The increasing complexity of interstitial lung disease (ILD) related to cancer‐targeted monoclonal antibodies (mAbs) has emerged as a significant clinical concern. Thus, this study aimed to investigate reporting signals of four ILD subtypes detected with cancer‐targeted mAbs.
Jinyoung Jeong +7 more
wiley +1 more source
NIMG-47. VOLUMETRIC ANALYSIS OF PHASE 2 AND 3 TRIALS IN RECURRENT GLIOBLASTOMA TREATED WITH VB-111 WITH OR WITHOUT BEVACIZUMAB OR BEVACIZUMAB MONOTHERAPY [PDF]
, 2019 Benjamin M. Ellingson +12 more
openalex +1 more source
Renal cell carcinoma with atypical omental metastasis: A case report and literature review
UroPrecision, EarlyView.Abstract Background Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, with common metastatic sites including the lungs, bones, liver, and brain. Omental metastasis is exceedingly rare and usually occurs postoperatively. Fumarate hydratase‐deficient (FH‐deficient) RCC, a recently classified and highly aggressive subtype of ...
Andrew Jing +4 more
wiley +1 more source
Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers. [PDF]
Clin Transl MedLamia MR +6 more
europepmc +1 more source